| Cat.No. | Name | Information |
|---|---|---|
| M1732 | Talazoparib (BMN-673) | Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity. |
| M3932 | NVP-TNKS656 | NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM; > 300 fold selectivity against PARP1 and PARP2. |
| M4931 | Rucaparib | Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1, also showing binding affinity to eight other PARP domains. |
| M1664 | AZD2281 (Olaparib) | AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator. |
| M2215 | Niraparib (MK-4827) | MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1. |
| M1785 | INO-1001 | INO-1001 is a novel poly(ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 3 nM. |
| M13713 | RK-287107 | RK-287107 is a potent and specific tankyrase inhibitor with IC50s of 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively. RK-287107 blocks colorectal cancer cell growth. |
| M27685 | Niraparib (R-enantiomer) | Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent PARP1 inhibitor with IC50 of 2.4 nM. |
| M27655 | OUL245 | OUL245 is a 7-Hydroxy derivative, and a selectively PARP2 inhibitor (IC50=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC50s of 2.9-8.8 μM. |
| M22487 | RBN-3143 | RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. |
| M21630 | NMS-P515 | NMS-P515 is a potent inhibitor of PARP-1 both in biochemical (Kd: 0.016 μM) and cellular (IC50: 0.027 μM) assays. |
| M21589 | OM-153 | OM-153 is a potent, orally active tankyrase inhibitor with IC50 of 13 nM for tankyrase 1 and 2 nM for tankyrase 2 (TNKS1/2). OM-153 inhibited luciferase based Wnt/β-catenin signal transduction reporter activity with IC50 of 0.63 nM. OM-153 inhibits Wnt/β-catenin signal transduction and proliferation in COLO 320DM. |
| M21447 | Amelparib | Amelparib is a potent, water soluble PARP-1 inhibitor with oral activity. |
| M19454 | Wistin | Wistin, isolated from Caragana sinica roots, is a PPARα and PPARγ agonist. |
| M19266 | Ankaflavin | Ankaflavin is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. |
| M19240 | Fucosterol | Fucosterol exhibits antioxidant, anti-adipogenic, blood cholesterol reducing, anti-diabetic and anti-cancer activities. Fucosterol regulates adipogenesis via inhibition of PPARα and C/EBPα expression. |
| M13715 | Veliparib dihydrochloride | Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively. |
| M13712 | PARP1-IN-5 dihydrochloride | PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer. |
| M13710 | iRucaparib-AP6 | iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
